Your browser is no longer supported. Please, upgrade your browser.
ABBV AbbVie Inc. daily Stock Chart
AbbVie Inc.
IndexS&P 500 P/E47.27 EPS (ttm)1.28 Insider Own0.10% Shs Outstand1.66B Perf Week-0.35%
Market Cap100.14B Forward P/E12.04 EPS next Y5.03 Insider Trans-11.97% Shs Float1.63B Perf Month-13.24%
Income2.08B PEG2.76 EPS next Q1.06 Inst Own74.90% Short Float2.24% Perf Quarter-9.71%
Sales20.99B P/S4.77 EPS this Y-57.20% Inst Trans7.14% Short Ratio4.14 Perf Half Y1.21%
Book/sh3.40 P/B17.79 EPS next Y18.07% ROA6.10% Target Price76.93 Perf Year12.44%
Cash/sh5.00 P/C12.10 EPS next 5Y17.12% ROE62.80% 52W Range50.87 - 71.60 Perf YTD-6.08%
Dividend2.04 P/FCF- EPS past 5Y-17.80% ROI16.80% 52W High-15.50% Beta-
Dividend %3.37% Quick Ratio1.40 Sales past 5Y7.00% Gross Margin80.70% 52W Low18.93% ATR2.18
Employees26000 Current Ratio1.50 Sales Q/Q11.10% Oper. Margin22.50% RSI (14)30.32 Volatility2.85% 3.15%
OptionableYes Debt/Eq5.65 EPS Q/Q23.50% Profit Margin9.90% Rel Volume1.40 Prev Close62.41
ShortableYes LT Debt/Eq4.93 EarningsJul 24 BMO Payout144.20% Avg Volume8.84M Price60.50
Recom2.20 SMA20-9.70% SMA50-11.45% SMA200-5.47% Volume12,538,100 Change-3.06%
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Jul-28-14Upgrade UBS Neutral → Buy $57 → $67
Jun-24-14Reiterated Argus Buy $59 → $65
Jan-06-14Reiterated UBS Neutral $46 → $56
Oct-29-13Reiterated Argus Buy $52 → $59
Aug-12-13Initiated Argus Buy $52
May-15-13Reiterated R. F. Lafferty Buy $47.90 → $61
Apr-29-13Reiterated Barclays Equal Weight $41 → $44
Apr-15-13Reiterated Barclays Equal Weight $37 → $41
Sep-01-15 03:57PM  The End Of Humiras Patent - Is AbbVie Prepared?
07:30AM  U.S. Food and Drug Administration Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies Business Wire
Aug-26-15 08:05AM  Short Sellers Have Mixed Feelings on Major Pharma at 24/7 Wall St.
Aug-25-15 11:09AM  Acorda Stock Jumps After Bass Patent Petitions Nixed at Investor's Business Daily
Aug-24-15 10:22AM  Medivation Buying Breast-Cancer Drug From BioMarin at Investor's Business Daily
09:00AM  Heres what Alphabets non-Google business models are going to look like at Fortune
Aug-22-15 07:37AM  A $25 Billion Hedge Fund Just Made AbbVie One of Its Biggest Bets at Motley Fool
Aug-21-15 10:15AM  AbbVie or Baxalta: Which Is the Better Biopharma Investment Today? at TheStreet
08:21AM  Did AbbVie Just Make an Incredibly Brilliant Decision? at Motley Fool
Aug-20-15 02:35PM  Billionaire Larry Robbins Has Healthy Stakes In Health Stocks at Insider Monkey
Aug-19-15 03:00PM  How Duke Fuqua profs connect to a $350M pharma transaction at
11:43AM  AbbVie Pays $350 Mil For United Therapeutics Voucher at Investor's Business Daily
10:41AM  AbbVie buys special review voucher for $350 mln Reuters
09:27AM  Hedge Funds Are Pouring Money Into These Stocks at Insider Monkey
08:33AM  Biotech Stock Roundup: Kite Addresses Patient Death Concerns, Omeros Soars on Data
06:45AM  United Therapeutics Sells Priority-Review Voucher to AbbVie at The Wall Street Journal
06:00AM  United Therapeutics Corporation Agrees to Sell Priority Review Voucher to AbbVie for $350 Million PR Newswire
Aug-18-15 11:21AM  3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever at Motley Fool
10:33AM  Wait, There are Still Cheap Pharma Stocks? at
08:22AM  4 Top Pharma Stocks That Should Outperform Out To 2016 at 24/7 Wall St.
Aug-17-15 05:56PM  First Eagle Investment Buys 19 Stakes in Second Quarter
04:54PM  Follow The Leaders: Watch Out For Best Stocks In Top Industries
12:48PM  AbbVie Challenges Fairness Of Upcoming Testosterone Trials at Forbes
11:51AM  Who Should Allergan Buy? at
11:08AM  Westport Asset Management Sells Bulk of Two Stakes
Aug-15-15 01:04PM  ABBVIE INC. Financials
Aug-13-15 04:30PM  AbbVie/Roche's Leukemia Drug Hits Phase II Primary Endpoint
Aug-12-15 04:09PM  Genentech cranks up partnerships for new generation of cancer drugs at
10:39AM  AbbVie to seek approval for potential blockbuster leukemia drug Reuters
09:45AM  Short Sellers Back Off Big Pharma at 24/7 Wall St.
09:41AM  Top US senator rails at CF Industries' plan to redomicile to UK at Financial Times
09:25AM  AbbVie to seek FDA approval for leukemia drug after trial success Reuters
08:30AM  Phase 2 Study of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion Meets Primary Endpoint PR Newswire
08:15AM  Here's Why Enanta Pharmaceuticals Stock Beat the Downtrend in July at Motley Fool
Aug-11-15 04:28PM  Halozyme Stock Reverses Despite AbbVie-Fueled Earnings at Investor's Business Daily
12:50PM  Why Halozyme Shares Jumped 10% Today at Motley Fool
08:13AM  Once Disparaged, 'Me-Too' Drugs Crucial For Lower Costs Of Cholesterol, Hepatitis C And Cancer Drugs at Forbes
Aug-10-15 03:19PM  Why AbbVie Should Be Worth 25% More at 24/7 Wall St.
Aug-07-15 05:01PM  ABBVIE INC. Files SEC form 8-K/A, Financial Statements and Exhibits
02:01PM  ABBVIE INC. Files SEC form 10-Q, Quarterly Report
01:00PM  Whats Shires plan for Baxalta? Inside CEO Flemming Ornskovs head at
Aug-06-15 12:33PM  5 Big Stocks to Trade for Big Gains -- Must-See Charts at TheStreet
07:26AM  Infinity Pharmaceuticals' Stock Dipped 15% in July: Time to Buy? at Motley Fool
Aug-05-15 12:33AM  Shire Makes Unsolicited $30.6 Billion Bid for Baxalta at The Wall Street Journal
Aug-04-15 07:56PM  Shire Mounts $30.6 Billion Bid for Biotech at The Wall Street Journal
04:07PM  Drugmaker Shire bids $30 bln for Baxter spin-off Baxalta Reuters
02:53PM  Shire in $30bn hostile approach for Baxalta at Financial Times
01:09PM  Shire/Baxalta: merry-go-round at Financial Times
12:54PM  Shire's Baxalta Offer Has 'Low Odds Of Success': Leerink at
Aug-03-15 12:55PM  AbbVie, Inc. Earnings Q2*, 2015
12:28PM  Shire buys US eyecare business for $300m at Financial Times
Jul-31-15 06:07PM  Highway Bill to Spend $500 Million for Veterans Hepatitis Drugs at Bloomberg
Jul-30-15 12:20PM  NBIX: Three More Data Readouts Coming in the Second Half of 2015 - Analyst Blog
11:30AM  NBIX: Three More Data Readouts Coming in the Second Half of 2015
09:30AM  The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases
08:04AM  Gilead's Hepatitis C Dominance Unchecked By AbbVie at Motley Fool
Jul-29-15 11:48AM  Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog
11:20AM  AbbVie (ABBV) Stock Price Target Raised at Deutsche Bank at TheStreet
09:40AM  Gilead (GILD) Beats on Q2 Earnings, Raises 2015 Outlook - Analyst Blog
09:04AM  Eli Lilly & Co. Earnings Analysis: By the Numbers
09:03AM  Bristol-Myers Squibb Co. Earnings Analysis: By the Numbers
Jul-28-15 06:53PM  Gilead Lifts Sales View As Hep C Drugs Top
05:12PM  Gilead higher after earnings beat
05:03PM  Express Scripts Raises Guidance as Earnings Top Views at The Wall Street Journal
04:28PM  Leon Cooperman: Allergan trying to move up
04:22PM  Gilead Sales Soar on Hepatitis Drugs at The Wall Street Journal
01:33PM  Gilead Sciences: How Will the Market React to Slowing U.S. Hep-C Sales? at
11:15AM  New drug approval is a win for the Bay State's horse in the hepatitis C race at
09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Merck, Achillion Pharmaceuticals and Express Scripts - Press Releases
06:31AM  Merck Targets Toughest Cases for Foothold in Hepatitis C Market at Bloomberg
Jul-27-15 05:16PM  Gilead Sciences: Sure, It's Hep-C But It's Not Just Hep-C at
03:24PM  Is Gilead Sciences About to Make an Acquisition?
01:51PM  4 Stocks to Fight the Virus on World Hepatitis Day - Analyst Blog
11:45AM  Biogen: Buy the Stock Get the Pipeline for Free at
10:42AM  3 Signs That the Healthcare Stock Bubble Might Have Just Popped at Motley Fool
10:10AM  Company News for July 27, 2015 - Corporate Summary
08:21AM  Short Sellers Run For Cover From Major Pharma at 24/7 Wall St.
07:00AM  European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization Application for Empliciti (elotuzumab) For the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies Business Wire
06:06AM  Allergan sells generic drugs unit to Teva for $40bn at Financial Times
04:25AM  Biotech high flyers face gravity test at Financial Times
Jul-24-15 05:42PM  UPDATE 2-AbbVie, Bristol-Myers get FDA nod for hep C treatments Reuters
03:44PM  AbbVie (ABBV) Earnings Report: Q2 2015 Conference Call Transcript at TheStreet
03:20PM  AbbVie's Investments Begin Kicking In at Motley Fool
02:00PM  TECHNIVIE (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA Approval as the First and Only All-Oral, Interferon-Free Treatment for Genotype 4 Chronic Hepatitis C in the U.S. PR Newswire
01:37PM  Edited Transcript of ABBV earnings conference call or presentation 24-Jul-15 1:00pm GMT
01:20PM  Biogen's Big-Volume Plunge Marks End Of 5-Year Run
12:33PM  AbbVie's revenue miss raises concerns over Humira sales
11:44AM  Biogen Plunges On Slashed Guidance; AbbVie Q2 Mixed at Investor's Business Daily
11:33AM  AbbVie (ABBV) Stock Sliding Following Second Quarter Earnings Results at TheStreet
11:12AM  AbbVie: Beware the Biosimilars? at
10:39AM  AbbVie Tops Earnings, Misses on Revenues, Maintains View - Analyst Blog
09:16AM  AbbVie (ABBV) Tops 2Q Earnings but Misses Revenues - Tale of the Tape
09:10AM  Are AbbVie Earnings Enough?
09:00AM  AbbVie Inc Earnings Call scheduled for 9:00 am ET today
08:38AM  AbbVie beats 2Q profit forecasts, but sales fall short
08:26AM  AbbVie's Revenue Growth Misses Expectations at The Wall Street Journal
08:11AM  ABBVIE INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:07AM  AbbVie beats 2Q profit forecasts
08:06AM  AbbVie's stock drops after sales miss expectations at MarketWatch
07:59AM  AbbVie Profit Tops Analysts Estimates as Drug Sales Rise 11% at Bloomberg
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company's products include HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, including those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants. It also provides AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and the treatment of endometriosis and central precocious puberty, as well as for the preoperative treatment of patients with anemia. In addition, the company offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, Niaspan, Simcor, and Advicor to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has strategic collaboration with Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, Alvine Pharmaceuticals, Inc., and Action Pharma A/S. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Option Exercise35.8865,0002,332,200538,187Jul 31 05:41 PM
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Sale71.2440,0212,851,264473,187Jul 31 05:41 PM
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Sale71.0924,9791,775,656513,208Jul 31 05:41 PM
HURWICH THOMAS A.VP, ControllerMay 19Option Exercise22.946,200142,23274,660May 21 05:50 PM
HURWICH THOMAS A.VP, ControllerMay 19Sale66.006,200409,20068,460May 21 05:50 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Option Exercise35.88175,4776,296,115657,624Apr 30 06:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Sale64.6795,9706,206,473554,660Apr 30 06:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Sale64.928,281537,569482,147Apr 30 06:02 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 08Sale64.726,994452,652561,360Apr 30 06:01 PM
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GCMar 02Sale60.3025,0001,507,500274,116Mar 03 06:10 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesMar 02Sale60.3012,314742,534106,954Mar 03 06:07 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 27Sale60.512,074125,492123,860Mar 03 06:07 PM
HURWICH THOMAS A.VP, ControllerFeb 27Sale60.571,18571,77770,322Mar 03 06:06 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 27Sale60.472,112127,706104,555Mar 03 06:09 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 17Sale58.7024114,147106,592Feb 19 05:51 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 09Option Exercise24.072,25054,1643,168Feb 11 05:28 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 22Option Exercise24.078,495204,501188,563Dec 22 05:22 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 22Sale68.008,495577,660180,068Dec 22 05:22 PM
HURWICH THOMAS A.VP, ControllerNov 24Sale67.811,500101,71763,211Nov 26 05:00 PM
HURWICH THOMAS A.VP, ControllerNov 06Option Exercise24.0710,000240,73171,448Nov 07 05:57 PM